Frailty and muscle loss may predict outcomes in lung scarring patients
NCT ID NCT07004595
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 100 adults aged 65 and older with fibrosing interstitial lung disease, a condition that scars the lungs and shortens life. Researchers will assess frailty and muscle loss (sarcopenia) using questionnaires and tests to see if these factors predict hospital stays, disease worsening, or death. The goal is to help doctors tailor care for those most at risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which patients need extra support or different treatments based on frailty and muscle loss.
- What could go wrong
- This is an observational study with only 100 participants, so results may not apply to everyone. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSING INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Nantes - Respiratory Department
RECRUITINGNantes, Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can nerve changes explain Age-Related muscle loss?
- Muscle loss in aging: can diet and exercise turn back the clock?
- Could a simple CT scan reveal which ICU cancer patients are at highest risk?
- Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
- Can surgery for stomach or esophageal cancer cloud the mind?